<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="pandemic as people have been eagerly trickling out from federally-mandated" exact="quarantine" post="into restaurants, bars, and gyms across America. History can"/>
 <result pre="review will cover our current understanding of the pathology and" exact="treatment" post="for COVID-19 and highlight similarities between past pandemics. By"/>
 <result pre="Spanish flu began from a zoonotic transmission, progressed rapidly from" exact="infection" post="to symptom onset with viral consolidation in the lung,"/>
 <result pre="is present in various organs throughout the body making multi-organ" exact="infection" post="possible ACE2 is a type 1 integral membrane protein"/>
 <result pre="ACE2. After binding and proteolytic processing, the final step for" exact="infection" post="is the viral entry into the host cell. It"/>
 <result pre="including the regions that encode this specific SP variant. Reverse-transcriptase" exact="polymerase chain reaction" post="(RT-PCR) recognizes the SP of SARS-Cov-2 and measures total"/>
 <result pre="expression and viral load are highest at the onset of" exact="infection" post="and lowest during recovery [22]. Elevated viral load thus"/>
 <result pre="of ACE2 may be an indicator of resistance to SARS-Cov-2" exact="infection" post="or a prognostic marker whereby increased expression correlates with"/>
 <result pre="SARS-Cov-2, mice expressing human ACE2 rapidly display signs of lethal" exact="infection" post="in the lungs and brain, whereas mice expressing murine"/>
 <result pre="and brain, whereas mice expressing murine ACE2 do not develop" exact="infection" post="[28]. In the transgenic mice, there is a rapid"/>
 <result pre="and 2.7â€‰Ã—â€‰105 copies per gram of tissue, respectively [30â€&quot;32]. The" exact="prevalence" post="of SP-ACE2 binding in these organs explains their substantial"/>
 <result pre="Get Sick Trying The lungs are the primary site of" exact="infection" post="and nearly all patients with COVID-19 present with some"/>
 <result pre="pneumocytes explains the susceptibility of the lungs to SP-mediated SARS-Cov-2" exact="infection" post="[35]. Well-differentiated type 2 pneumocytes express ACE2 more abundantly"/>
 <result pre="SARS-Cov-2-induced pneumonia currently results in death within 28 days of" exact="diagnosis" post="and 7 days of admission to the intensive care"/>
 <result pre="The potent binding of SP to ACE2 and subsequent cellular" exact="infection" post="may explain the prevalence of respiratory symptoms in COVID-19"/>
 <result pre="SP to ACE2 and subsequent cellular infection may explain the" exact="prevalence" post="of respiratory symptoms in COVID-19 patients. Transgenic mice expressing"/>
 <result pre="adult and adolescent lung tissue that either predisposes adults to" exact="infection" post="or protect adolescents. While the severity of respiratory symptoms"/>
 <result pre="admission and death [43]. Thus, a more widespread SARS-Cov-2 lung" exact="infection" post="correlates with worse outcomes. Ultrasound is another valuable imaging"/>
 <result pre="activity [48]. This contradictory mechanism highlights the complexity of SARS-Cov-2" exact="infection" post="in the respiratory tract. Ideal survival conditions depend on"/>
 <result pre="to continue to investigate the pathology and treatments for SARS-Cov-2" exact="infection" post="in the lungs as the primary target of the"/>
 <result pre="on SARS-CoV-2 found that 78 out of 214 patients demonstrated" exact="infection" post="of the central nervous system (CNS). More severe patients"/>
 <result pre="Mice administered low concentration of MERS-CoV intranasally only displayed viral" exact="infection" post="of the CNS, not the lungs, indicating that the"/>
 <result pre="now suggests coronaviruses enter the CNS via synaptic avenues upon" exact="infection" post="of peripheral nerve terminals [55]. Swine hemagglutinating encephalomyelitis virus"/>
 <result pre="SARS-CoV-2 may provide insight to better mitigate symptoms and prevent" exact="infection" post="in humans. Cardiac involvement in SARS-CoV-2 infection is prevalent"/>
 <result pre="symptoms and prevent infection in humans. Cardiac involvement in SARS-CoV-2" exact="infection" post="is prevalent among patients [56]. As noted above, the"/>
 <result pre="has the propensity to damage the heart without direct viral" exact="infection" post="of the tissue [57]. Direct SARS-CoV-2 infection, hypoxemia, and"/>
 <result pre="myocardial complications. Cell populations in the heart most vulnerable to" exact="infection" post="may be distinguished by expression of ACE2. For instance,"/>
 <result pre="expression of ACE2. For instance, myocardial pericytes express ACE2, and" exact="infection" post="or disruption caused by inflammation may lead to ischemic"/>
 <result pre="SP-ACE2 mediated cellular infection. SP is critical to extrapulmonary organ" exact="infection" post="due to its ability to promote viral uptake in"/>
 <result pre="SP binding due to their elevated ACE2 expression, and pericyte" exact="infection" post="results in microvascular dysfunction that worsens cardiac symptoms [58]"/>
 <result pre="results in microvascular dysfunction that worsens cardiac symptoms [58] Therefore," exact="infection" post="of non-lung organs may further exacerbate pulmonary infection and"/>
 <result pre="[58] Therefore, infection of non-lung organs may further exacerbate pulmonary" exact="infection" post="and other comorbidities such as cardiovascular and cerebrovascular diseases."/>
 <result pre="serum of these patients [71]. The cardiovascular repercussions of COVID-19" exact="infection" post="may be primarily due to the presence of the"/>
 <result pre="virus [74]. On average, stroke occurred 12 days post COVID-19" exact="diagnosis" post="[74]. In Italy, ischemic stroke appeared at a rate"/>
 <result pre="cases in Wuhan [75]. In addition to acute repercussions, COVID-19" exact="infection" post="may have chronic neurological consequences. Although a direct link"/>
 <result pre="and multiple sclerosis (MS) has been explored. An OC43 coronavirus" exact="detection" post="test was conducted on human brain autopsy samples for"/>
 <result pre="Although the exact mechanism mediating the chronic manifestations of SARS-CoV-2" exact="infection" post="is currently unknown, the interaction of SP and ACE2"/>
 <result pre="public. These measures, more commonly known to the public as" exact="social distancing," post="are implemented to reduce the number of interactions between"/>
 <result pre="spreading the disease to people in the port city. This" exact="quarantine" post="method was also implemented during the SARS epidemic in"/>
 <result pre="crucial if they are infected with a disease. During the" exact="quarantine" post="period, individuals are carefully monitored for signs of any"/>
 <result pre="were subjected to a mandatory 2-week quarantine. Some countries used" exact="isolation" post="tents to conduct the 2-week quarantine while others simply"/>
 <result pre="quarantine. Some countries used isolation tents to conduct the 2-week" exact="quarantine" post="while others simply strongly recommended individuals to self-isolate at"/>
 <result pre="to self-isolate at home. Quantitative assessments of the effectiveness of" exact="quarantine" post="may provide empirical evidence for the recommended guidelines. The"/>
 <result pre="after these measures, however, they are only effective if the" exact="isolation" post="period is long enough [80]. Good hygiene also plays"/>
 <result pre="to wear a face mask in public areas, and practicing" exact="social distancing" post="guidelines are all efficient ways to protect from COVID-19."/>
 <result pre="is no vaccine that prevents COVID-19. While human behaviors, including" exact="social distancing" post="and proper hygiene that plagued the Spanish flu, remain"/>
 <result pre="as well as a potential for speed. Moderna began clinical" exact="testing" post="only 2 months after sequence identification. Platforms based on"/>
 <result pre="from binding to ACE2 and entering host cells, thus preventing" exact="infection" post="from occurring [84]. Polyclonal murine antibodies against SP already"/>
 <result pre="responsible for the continuous monitoring of antiviral drugs for clinical" exact="treatment" post="[86]. Two antiviral compounds, M2 ion channel blockers (adamantanes)"/>
 <result pre="and NA inhibitors are the current options available to combat" exact="infection" post="and counteract the spread of viruses. Adamantanes are commonly"/>
 <result pre="zanamivir, favipiravir, baloxavir, and pimodivir sheds new light on the" exact="treatment" post="for influenza. There is currently no proven effective antiviral"/>
 <result pre="treatment for influenza. There is currently no proven effective antiviral" exact="treatment" post="for COVID-19. However, many antiviral treatments have demonstrated efficacy"/>
 <result pre="COVID-19. However, many antiviral treatments have demonstrated efficacy for the" exact="treatment" post="of COVID-19 including lopinavir and ritonavir, chloroquine, and hydroxychloroquine"/>
 <result pre="alleviate symptoms in patients. With over 300 clinical trials currently" exact="testing" post="various antiviral drugs, treatment has focused on the uses"/>
 <result pre="With over 300 clinical trials currently testing various antiviral drugs," exact="treatment" post="has focused on the uses of chloroquine, hydroxychloroquine, lopinavir/ritonavir,"/>
 <result pre="similar chemical structures and have been commonly used for the" exact="treatment" post="of rheumatoid arthritis and malaria [88]. Their mechanism and"/>
 <result pre="the potential use of chloroquine in the early stages of" exact="infection" post="before the virus can reduce ACE2 expression and activity"/>
 <result pre="has authorized the use of chloroquine and hydroxychloroquine for emergency" exact="treatment" post="of COVID-19 and has the potential to decrease symptoms"/>
 <result pre="in treating COVID-19. Another antiviral drug being explored for the" exact="treatment" post="of COVID-19 is lopinavir/ritonavir (LPV/r). Lopinavir is a protease"/>
 <result pre="a booster and they are commonly used to treat HIV" exact="infection" post="in combination. In vitro studies have demonstrated the ability"/>
 <result pre="with LPV/r and ribavirin [88]. The use of LPV/r for" exact="treatment" post="of COVID-19 has proven effective in combined therapy for"/>
 <result pre="clinical condition of SARS-CoV patients and serves as a viable" exact="treatment" post="option in COVID-19 infections [91]. Favipiravir (brand name Avigan)"/>
 <result pre="(brand name Avigan) has been developed and used for the" exact="treatment" post="of avian influenza or other types of influenza that"/>
 <result pre="knowledge has been produced to recommend favipiravir as an effective" exact="treatment" post="[88]. Remdesivir is another novel antiviral drug that was"/>
 <result pre="another novel antiviral drug that was originally developed for the" exact="treatment" post="of the disease Ebola. Remdesivir can inhibit viral RNA"/>
 <result pre="has widespread activity usage against filoviruses and coronaviruses. In vitro" exact="testing" post="has developed to demonstrate remdesivir activity against SARS-Cov-2 and"/>
 <result pre="registered on ClinicalTrials.gov [88]. Remdesivir serves as a promising therapeutic" exact="treatment" post="for COVID-19. Additionally, oseltamivir (Tamiflu), which is approved for"/>
 <result pre="for COVID-19. Additionally, oseltamivir (Tamiflu), which is approved for the" exact="treatment" post="of influenza A and B, is used to target"/>
 <result pre="administering oseltamivir and it does not serve as a recommended" exact="treatment" post="for COVID-19 [88]. A potential target for drug development"/>
 <result pre="hydrochloride serves as a candidate drug combination against the SARS-CoV-2" exact="infection" post="with access through ACE2 [90]. The ability to weaken"/>
 <result pre="over 300 clinical trials targeting various antiviral medications for the" exact="treatment" post="of COVID-19, there are still no final verified antivirals"/>
 <result pre="are still no final verified antivirals specific to COVID-19. Further" exact="testing" post="is still needed to explore the efficacy and safety"/>
 <result pre="drugs with appropriate pharmacological effects and therapeutic efficiencies in the" exact="treatment" post="of COVID-19 patients [89]. The antiviral drugs being explored"/>
 <result pre="favipivir, and lopinavir and ritonavir can be administered for the" exact="treatment" post="of severe COVID-19 pneumonia and to lower the mortality"/>
 <result pre="mortality rate of the disease [90]. To this end, antiviral" exact="treatment" post="of COVID-19 is promising, with several potential drug candidates"/>
 <result pre="Overall, the repurposing of available drugs for immediate use of" exact="treatment" post="for COVID-19 could improve the currently available clinical management."/>
 <result pre="discoveries on plasma therapy, if plasma therapy became an available" exact="treatment" post="option for COVID-19 patients, convalescent plasma therapy should be"/>
 <result pre="response and overreaction of the immune system to the increased" exact="infection" post="and cell death would further cause pulmonary damage, possibly"/>
 <result pre="patients was nearly undetectable and assumed to be eliminated after" exact="treatment" post="[102, 104]. Despite different dosage of plasma, ranging from"/>
 <result pre="Chinese patients with severe cases of COVID-19 received convalescent plasma" exact="treatment" post="after approximately 16 days of contraction [102]. 200-mL convalescent"/>
 <result pre="symptoms significantly improved in all patients 3 days after receiving" exact="treatment" post="followed by no traces of SARS-CoV-2 after one week."/>
 <result pre="saturation and lymphocyte counts, due to antibodies obtained from the" exact="treatment" post="highlight decreased inflammation and hyperactivity of the immune system"/>
 <result pre="plasma, which was administered twice in 12-hour intervals. Patients received" exact="treatment" post="at different times: one receiving 22 days after onset"/>
 <result pre="from earlier pandemics and studies regarding convalescent plasma treatment. Earlier" exact="treatment" post="after exposure to SARS-CoV-2 was more effective compared to"/>
 <result pre="standard care while also receiving plasma therapy, such as antiviral" exact="treatment" post="[102]. Indeed, this opens the possibility of antiviral treatment"/>
 <result pre="antiviral treatment [102]. Indeed, this opens the possibility of antiviral" exact="treatment" post="contributing to the recovery of the patients. However, this"/>
 <result pre="to other patients [101, 102]. For patients who received plasma" exact="treatment" post="late, it is difficult to determine whether their recovery"/>
 <result pre="to convalescent plasma or natural recovery. The varying times of" exact="treatment" post="along with limited human trials limit the potential of"/>
 <result pre="impart protection by attenuating inflammation and are being explored as" exact="treatment" post="options for COVID-19 in clinical trials (Table 1). Preclinical"/>
 <result pre="clinical improvements for COVID-19 patients are to be monitored after" exact="treatment" post="with (NHPBSCs). Patient immune profile will be evaluated, measuring"/>
 <result pre="/kg to severe COVID-19 patients. Safety and efficacy of cell-based" exact="treatment" post="assessed through clinical symptom amelioration, frequency of adverse events,"/>
 <result pre="mesenchymal stem cells Phase II COVID-19 patients will receive intravenous" exact="treatment" post="of UC-MSCs at a dose of 5 x 10^5"/>
 <result pre="cord-derived mesenchymal stem cells Phase I In conjunction with standardized" exact="treatment" post="(Oseltamivir + Azithromycin), patients will be treated with intravenous"/>
 <result pre="intravenously delivered to COVID-19 patients. Clinical improvement following stem cell" exact="treatment" post="will be assessed via frequency of adverse incidents, mortality"/>
 <result pre="receive two doses of WJ-MSCs (50*10e6 cells) along with standardized" exact="treatment" post="of hydroxychloroquine and Lopinavir/Ritonavir or Azithromycin and ventilator support."/>
 <result pre="behave similarly to ESCs [110]. They show promise in the" exact="treatment" post="of degenerative disorders due to their self-renewal and differentiative"/>
 <result pre="interaction between the viral SP and human ACE2 initiates the" exact="infection" post="of host cells [124]. Once the virus enters the"/>
 <result pre="COVID-19 causes pulmonary damage as well as cardiovascular and cerebrovascular" exact="infection" post="by overreacting the immune system and increasing inflammation, MSC"/>
 <result pre="Phase 1 dose-escalation study showed no safety issues for the" exact="treatment" post="of ARDS with BMSCs (NCT 01775774) [127]. Furthermore, high-dose"/>
 <result pre="the phase IIa study, there were no statistical differences between" exact="treatment" post="and placebo groups in mortality and the number of"/>
 <result pre="stay remained unchanged (NCT01902082) [129]. Although the efficacy of the" exact="treatment" post="of lung diseases with MSCs is not yet conclusive,"/>
 <result pre="because inflammation is an evolving, progressive, and chronic pathology, prolonged" exact="treatment" post="through repeated administration of MSCs may be necessary for"/>
 <result pre="of MSCs renders it a promising option as a novel" exact="treatment" post="method for COVID-19. Although there are currently 43 proposed"/>
 <result pre="further supports the potential of stem cells as an effective" exact="treatment" post="[138]. Stem cells are at the forefront of innovative"/>
 <result pre="the brainstem cardiorespiratory center via neuronal synapses. This multi-organ, heart-brain" exact="infection" post="may exacerbate respiratory failure. The critical entry receptor for"/>
 <result pre="best course of action in the meantime is to continue" exact="social distancing," post="practice good hygiene, and most importantly, check our disillusioned"/>
 <result pre="C., Zhu, L., Guo, Y., &amp;amp; Zhang, F. (2020). Quantitative" exact="detection" post="and viral load analysis of SARS-CoV-2 in infected patients."/>
 <result pre="Virology20118594122413421325420 36.JiaHPLookDCShiLHickeyMPeweLNetlandJFarzanMWohlford-LenaneCPerlmanSMcCrayPBACE2 receptor expression and severe acute respiratory syndrome coronavirus" exact="infection" post="depend on differentiation of human airway epitheliaJournal of Virology20057923146141462116282461"/>
 <result pre="J. (2009). MicroRNome analysis unravels the molecular basis of SARS" exact="infection" post="in bronchoalveolar stem cells. PLoS One, 4(11), e7837. 48.ZieglerCGAllonSJNyquistSKMbanoIMMiaoVNTzouanasCNCaoYYousifASBalsJHauserBMFeldmanJMuusCWadsworthMHKazerSWHughesTKDoranBGatterGJVukovicMTaliaferroFMeadBEGeoZWangJPGrasDPlaisantMAnsariMAngelidisIAdlerHSucreJMTaylorCJLinBWaghrayAMitsialisVDwyerDFBuchheitKMBoyceJABarretNALaidlawTMCarrollSLColonnaLTkachevCPetersonCWYuAZhengHBGideonHPWinchellCGLinPLBingleCDSnapperSBKropskiJATheisFJSchillerHBZaragosiLBarbryPLeslieAKienHFlynnJLFortuneSMBergerBFinbergRWKeanLGarberMSchmidtALingwoodDShalekSARS-CoV-2"/>
 <result pre="patients with coronavirus disease 2019 in Wuhan, ChinaJAMA Neurology2020776683690 53.ChanPKToKLoAWCheungJLChuIAuFWTongJHTamJSSungJJNgHPersistent" exact="infection" post="of SARS coronavirus in colonic cells in vitroJournal of"/>
 <result pre="of the chemokine mig in pathogenesisClinical Infectious Disease200541810891096 55.LiYCBaiWHiranoNHayashidaTTaniguchiTSugotaYTohyamaKHashikawaTNeurotropic virus" exact="tracing" post="suggests a membranous-coating-mediated mechanism for transsynaptic communicationJournal of Comparative"/>
 <result pre="ill patients with COVID-19 in Washington StateJAMA20203231616121614 60.GaoQYChenYXFangJY2019 Novel coronavirus" exact="infection" post="and gastrointestinal tractJournal of Digestive Diseases202021312512632096611 61.DariyaBNagarajuGPUnderstanding novel COVID-19:"/>
 <result pre="65.SunJAghemoAFornerAValentiLCOVID-19 and liver diseaseLiver International20204061278128132251539 66.ZangRCastroMFMcCuneBTZengQRothlaufPWSonnekNMLiuZBruloisKFWangXGreenbergHBDiamondMSCiorbaMAWhelanSPDingSTMPRSS2 and TMPRSS4 promote SARS-CoV-2" exact="infection" post="of human small intestinal enterocytesScience Immunology2020547eabc358232404436 67.LauerSAGrantzKHBiQJonesFKZhengQMeredithHRAzmanASReichNGLesslerJThe incubation period"/>
 <result pre="78.TrillaATrillaGDaerCThe 1918 â€œSpanish fluâ€� in SpainClinical Infectious Diseases200847566867318652556 79.Wilder-SmithAFreedmanDOIsolation, quarantine," exact="social distancing" post="and community containment: pivotal role for old-style public health"/>
 <result pre="towards new therapeutic approachesCellullar and Molecular Life Sciences2014711936593683 88.Simsek YavuzSUnalSAntiviral" exact="treatment" post="of COVID-19Turkish Journal of Medical Sciences202050SI-161161932293834 89.Wu, R., Wang,"/>
 <result pre="&amp;amp; Therapeutics2020141586032147628 93.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGSeidahNGNicholSTChloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirology Journal2005216916115318 94.Fantini, J., Chahinian, H., &amp;amp; Yahi,"/>
 <result pre="Agents, 106020â€&quot;106020. 95.BlochEMShohamSCasadevallASachaisBSShazBWintersJLBuskirkCGrossmanBJJoynerMHendersonJPPekoszALauBWesolowskiAKatzLShanHAuwaerterPGThomansDSullivanDJPanethNGehrieRSpitalnikSHodEAPollackLNicholsonWTPirofskiLBaileyJATobianAADeployment of convalescent plasma for the prevention and" exact="treatment" post="of COVID-19Journal of Clinical Investigation202013062757276532254064 96.GarraudOHeshmatiFPozzettoBLefrereFGirotRSaillolALapercheSPlasma therapy against infectious"/>
 <result pre="I/II)Trials20202152032532356 111.SenguptaVSenguptaSLazoAWoodsPNolanABremerNExosomes derived from bone marrow mesenchymal stem cells as" exact="treatment" post="for severe COVID-19Stem Cells and Development2020291274775432380908 112.Tobin, M. K.,"/>
 <result pre="injury in miceJournal of Immunology2007179318551863 127.WilsonJGLiuKDZhouHCaballeroLMcMillanMFangXCosgroveKVojnikRCalfeeCSLeeJRogersAJLevittJWiener-KronishJBajwaEKLeavittAMcKennaDThompsonTMatthayMAMesenchymal stem (stromal) cells for" exact="treatment" post="of ARDS: a phase 1 clinical trialLancet Respiratory Medicine201531243225529339"/>
 <result pre="Disease202011221622832257537 135.SenguptaVSenguptaSLazoAWoodsPNolanABremerNExosomes derived from bone marrow mesenchymal stem cells as" exact="treatment" post="for severe COVID-19Stem Cells and Development2020291274775432380908 136.Liang, B., Chen,"/>
 <result pre="umbilical cord Whartonâ€™s jelly-derived mesenchymal stem cells as a potential" exact="treatment" post="for patients with COVID-19 pneumoniaStem Cell Research &amp;amp; Therapy202011120732460839"/>
</results>
